Abstract:Abstract Abstract Background: Chemokine (C-C Motif) Ligand 17 is a protein coding gene. This chemokine plays important roles in T cell development in thymus as well as in trafficking and activation of mature T cells. Diseases associated with CCL17 include mycosis fungoides, paragonimiasis and some hematologic malignancies such as Hodgkin¡¯s lymphoma, B cell lymphoma, and Nasal natural killer/T cell lymphoma (NNKTL). However, our knowledge of the expression levels of CCL17 in B-cell acute lymphoblastic leukemia (ALL) remains limited. Aims: The purpose of this study was to investigate the expression levels of human CCL17 messenger RNA in adult B-cell ALL. Methods: A real-time quantitative reverse transcription-polymerase chain reaction assay based on TaqMan fluorescence methodology was used to quantify the CCL17 mRNA copy number in the bone marrow cells from patients with adult leukemia and in 16 human hematologic malignant cell lines. Normal marrow samples from the allogeneic stem cell transplantation donors were served as control. Informed consent was obtained for every marrow sample. Results: Expression levels of the CCL17 gene in leukemic cell lines, leukemia patients and normal donor marrow are shown in Figure 1. These results showed that the relative levels of CCL17 gene expression in marrow from 189 newly diagnosed B-cell ALL(median 0.23%; range 0%¡«69000%) was significantly higher than those of bone marrow from the 43 healthy donors (median 0.05%; range 0%¡«6.87%;P =0.0007). Significant CCL17 mRNA overexpression was found in the de novo B-cell ALL patients compared with 102 treated B-cell ALL patients(median 0.02%; range 0%¡«3339%) who achieved complete remission or 70 de novo AML (median 0.02%; range 0%¡«9.132%;P¡¯s <0.0001). The expression levels of CCL17 was higher in 21 refractory/relapsed B-cell ALL patients (median 0.68%; range 0.003%¡«13490%) than that newly diagnosed B-cell ALL, but no statistical significant difference was observed (P=0.34). Besides, no statistical significant difference was observed in 16 newly diagnosed T-cell ALL(median 0.06%, range 0%¡«9.947%), 70 AML and 43 healthy donors (P¡¯s > 0.05), but it was higher in SupB15 and Nalm-6 cells from B-cell ALL cell lines than in other cells from AML or T-cell ALL cell lines. Conclusion: These results suggest that abnormal expression of CCL17 in leukemia may be involved in the pathomechanism of B-cell ALL. Figure 1 A: CCL17 expression levels in B-cell ALL and healthy donors( ** represent P< 0.01). B: CCL17 expression levels in human hematologic malignant cell lines. Figure 1. A: CCL17 expression levels in B-cell ALL and healthy donors( ** represent P< 0.01). / B: CCL17 expression levels in human hematologic malignant cell lines. Disclosures No relevant conflicts of interest to declare.

CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells.

Peg10 Activation by Co-Stimulation of Cxcr5 and Ccr7 Essentially Contributes to Resistance to Apoptosis in Cd19(+)Cd34(+) B Cells from Patients with B Cell Lineage Acute and Chronic Lymphocytic Leukemia

Retraction Note: Selectively Frequent Expression of CXCR5 Enhances Resistance to Apoptosis in CD8+CD34+ T Cells from Patients with T-cell-lineage Acute Lymphocytic Leukemia

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

Cc Chemokine Ligand 25 Enhances Resistance To Apoptosis In Cd4(+) T Cells From Patients With T-Cell Lineage Acute And Chronic Lymphocytic Leukemia By Means Of Livin Activation

CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia

Selectively Increased Expression and Functions of Chemokine Receptor CCR9 on CD4+ T Cells from Patients with T-cell Lineage Acute Lymphocytic Leukemia.

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia

CXCL13-CXCR5 axis：regulation in inflammatory diseases and cancer

CX3CR1 Positively Regulates BCR Signaling Coupled with Cell Metabolism Via Negatively Controlling Actin Remodeling

Analysis of the Expression Pattern of the BCL11B Gene and Its Relatives in Patients with T-cell Acute Lymphoblastic Leukemia

Abnormal Expression of the Chemokine (C-C Motif) Ligand 17 Gene in Adult B-Cell Acute Lymphoblastic Leukemia

High-Expressed CXCR7 Contributes to CXCL12-Mediated Protection from Apoptosis in Lymphoma Cells

Effect of Chemokine Receptors CCR7 on Disseminated Behavior of Human T cell Lymphoma: clinical and experimental study

Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.

CXCR5+CD8+ T Cells Present Elevated Capacity in Mediating Cytotoxicity Toward Autologous Tumor Cells Through Interleukin 10 in Diffuse Large B-cell Lymphoma.

CXCL13-CXCR5 Axis: Regulation in Inflammatory Diseases and Cancer.

Immunophenotype and Increased Presence of CD4(+)CD25(+) Regulatory T Cells in Patients with Acute Lymphoblastic Leukemia.

Differing Activities of Homeostatic Chemokines CCL19, CCL21, and CXCL12 in Lymphocyte and Dendritic Cell Recruitment and Lymphoid Neogenesis

The Expression Pattern of Bcl11a, Mdm2 and Pten Genes in B-cell Acute Lymphoblastic Leukemia.

CCR2 Expression Promotes Diffuse Large B Lymphoma Cell Survival and Invasion